Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elsulfavirine PK and Safety in Healthy and Hepatically Impaired Subjects
NCT03706898Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elsufavirine in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by Viriom Inc. Primary endpoints: Plasma concentration of elsulfavirine at 42 days, Plasma concentration of VM-1500A at 42 days and 3 more. Started Oct 2018; status: completed.
02
Drugs
elsufavirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03706898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706898.